NOV 09, 2017 12:00 PM PST

Understanding T Cell Responses in Tuberculosis-Latest research on QuantiFERON-TB Gold Plus

Speaker
  • Senior Director: Product and Assay Development North Americas, QIAGEN
    Biography
      Dr. Boyle has over 20 years of experience in immunology research and commercial development relevant to vaccines, biologics and diagnostics. He has published more than 25 papers including Nature, Proc. Natl. Acad. Sci., J. Clin. Microbiol., Vaccine, Int. Immunol. and Transplantation. In addition, he acquired several high-level awards, including top academic achievement each year of undergraduate studies and the Victorian Premiers award for Medical Research. Currently he has an assay development focus on utilizing whole blood assays of cellular immune function for providing insights into unmet medical needs in infectious diseases and transplantation. He is an inventor on several patents relevant to current products and played key roles in leading teams necessary for taking them from concept through to registration.

    Abstract

    QuantiFERON TB (QFT) was the first interferon gamma release assay (IGRA) utilizing whole blood stimulation as a test for TB infection, gaining FDA approval in 2001. Subsequently there have been several improvements to the first test in terms of accuracy, ease of use and clinical utility.  There are currently over 1200 independent publications on QFT and it is the most studied IGRA in the world on contact evaluation, epidemiology, vaccine and Pharma development and biomarker research. The 4th generation (QFT-Plus) is currently FDA approved in the USA and is CE marked in Europe. QFT-Plus provides higher specificity than the tuberculin skin test (TST) by incorporating highly specific antigens that do not cross react with BCG and most environmental non tuberculosis mycobacteria. In addition, it has new antigens that stimulate CD8 T cells.

    Published studies now supports a role for CD8+ T cells participating in the host defense to MTB by producing IFN-γ and other soluble factors, which activate macrophages to suppress growth of MTB, kill infected cells, or directly lyse intracellular MTB (1-3). MTB-specific CD8+ cells have been detected in subjects with LTBI and with active TB disease where IFN-γ producing CD8+ cells may be frequently found (4-6). Moreover, ESAT-6 and CFP-10 specific CD8+ T lymphocytes are described as being more frequently detected in subjects with active TB disease versus LTBI, and may be associated with a recent MTB exposure (7-9). In addition, MTB-specific CD8+ T cells producing IFN-γ have also been detected in active TB subjects with HIV co-infection (10, 11) and in young children with TB disease (12).  How the incorporation of novel CD8 antigen stimulation technology has proved beneficial in independent performance studies with QFT-Plus in active TB and contact investigations will be discussed.  Maintaining the performance and ease of use of whole blood stimulation builds on the value of QFT and will provide further benefit in the management of latent tuberculosis and TB control programs.


    Show Resources
    You May Also Like
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    APR 20, 2021 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 20, 2021 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    MAR 25, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAR 25, 2021 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: March 25, 2021 Time: 8:00am (PST), 11:00am (EST) Flow cytometry has expanded to have more users, more data, and multiple instrument types. While this has lead to more quantitative data...
    DEC 15, 2020 10:00 AM PST
    C.E. CREDITS
    DEC 15, 2020 10:00 AM PST
    DATE: December 15, 2020 TIME: 10:00am PST Scientists from Thermo Fisher Scientific will walk us through the world of microorganisms. They will discuss their most recent research on viruses,...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 09, 2017 12:00 PM PST

    Understanding T Cell Responses in Tuberculosis-Latest research on QuantiFERON-TB Gold Plus


    Specialty

    Immunology

    Infectious Disease

    Diagnostics

    Cell Biology

    Pcr/rt-Pcr/real-Time Pcr

    Biomarkers

    Biotechnology

    Biochemistry

    Microbiology

    Laboratory Testing

    Cell Culture

    Antibodies

    Clinical Diagnostics

    Clinical Research

    Assay Development

    Geography

    North America44%

    South America44%

    Africa11%

    Registration Source

    Website Visitors100%

    Job Title

    Medical Laboratory Technician38%

    Research Scientist25%

    Clinical Laboratory Scientist25%

    Facility/Department Manager13%

    Organization

    Government/public44%

    Diagnostic Company22%

    Non-Profit Organization11%

    Clinical Laboratory11%

    Government11%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more